Fidia S.p.A. (FRA:FIC0)
Germany · Delayed Price · Currency is EUR | Market Cap | 82.60K -92.4% |
| Revenue (ttm) | 21.13M -28.9% |
| Net Income | -2.19M |
| EPS | -1.15 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0002 |
| Previous Close | 0.0002 |
| Day's Range | 0.0002 - 0.0002 |
| 52-Week Range | 0.0001 - 0.5000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 29, 2026 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. The company offers HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; pushbutton panels; XPower digital drives for axis and spindle movement; and I/O Line input/output modules. It also provides software solutions include... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
AstraZeneca (AZN) Receives FDA Extension for Drug Review
AstraZeneca (AZN) Receives FDA Extension for Drug Review
Nuvalent (NUVL) Secures FDA Filing Acceptance for Neladalkib
Nuvalent (NUVL) Secures FDA Filing Acceptance for Neladalkib
FDA Extends Review Of AstraZeneca's Camizestrant NDA In ESR1-Mutated Advanced Breast Cancer
(RTTNews) - AstraZeneca (AZN, AZN.L) announced that the US Food and Drug Administration or FDA will extend the PDUFA date to review additional data requested to support the New Drug Application or NDA...
Top Biotech Gainers: CODX Soars On Ebola Assay Progress, NRXP Nears FDA Decision, NVAX On Watch
(RTTNews) - Today's Top Gainers list includes CODX, which is advancing the development of its Ebola PCR Assay; NRXP, which has a couple of near-term regulatory catalysts to watch; ECOR, whose latest S...
Dyne Therapeutics To Submit BLA To FDA For Z- Rostudirsen
(RTTNews) - Dyne Therapeutics, Inc. (DYN), a clinical-stage neuromuscular disease company, announced on Tuesday its submission of a Biologics License Application (BLA) to the U.S. Food and Drug Admini...
AstraZeneca: FDA Extends PDUFA Date Related To NDA For Camizestrant
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the FDA has informed that it will extend the PDUFA date to review additional data requested to support the New Drug Application for camizestra...
FDA advisers to weigh updated COVID vaccine targeting XFG subvariant
The Food and Drug Administration's (FDA) advisory committee on vaccines this week will consider whether to change the COVID-19 vaccine to target the XFG subvariant for the upcoming 2026-2027 respirato...
FDA to Discuss COVID Vaccine Targeting XFG Variant Ahead of 2026-2027 Season
FDA to Discuss COVID Vaccine Targeting XFG Variant Ahead of 2026-2027 Season
Spectral AI Stock Falls 12% Despite Winning FDA's De Novo Classification For Its DeepView System
(RTTNews) - Shares of Spectral AI, Inc. (MDAI) are falling about 12 percent in Tuesday morning trading after the company announced that the U.S. Food and Drug Administration granted De Novo Classifica...
Dyne Therapeutics (DYN) Seeks FDA Approval for Duchenne Muscular Dystrophy Treatment
Dyne Therapeutics (DYN) Seeks FDA Approval for Duchenne Muscular Dystrophy Treatment
Outlook Therapeutics Stock Climbs 38% After Winning FDA Appeal For NAMD Therapy
(RTTNews) - Shares of Outlook Therapeutics, Inc. (OTLK) are climbing about 38 percent in Tuesday morning trading after the company announced that the U.S. FDA has granted its appeal following completi...
Specialty beverages sold in 25 states recalled for possible contamination
(WHTM) – Various specialty beverages that were sold across 25 states have been recalled for possible contamination. According to the U.S. Food & Drug Administration (FDA), SKS Copack of Cerritos, Cali...
Outlook Therapeutics (OTLK) Gains FDA Appeal Approval for Lytenava
Outlook Therapeutics (OTLK) Gains FDA Appeal Approval for Lytenava
Outlook Therapeutics Wins FDA Appeal For NAMD Therapy; Stock Up
(RTTNews) - Outlook Therapeutics Inc. (OTLK) announced that the U.S. FDA has granted its appeal following completion of the Formal Dispute Resolution process for ONS-5010/LYTENAVA (bevacizumab-vikg). ...
Dr. Scott Gottlieb on Ebola outbreak: This is an outbreak that's out of control in West Africa
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the latest developments on the Ebola outbreak, risks to the United States, GLP-1's impact on cancer risks, and more.
The FDA opened a gaping loophole for flavored vapes
Federal regulators are allowing sales of unapproved e-cigarettes and nicotine pouches.
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Palantir Bulls Face a Reality Check Before EarningsInovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eig...
Abortion pill case widens anti-abortion activists’ rift with Trump
After a string of disappointments, conservative activists are demanding action from the FDA, DOJ and other agencies.
Trump's former COVID adviser: US equipped to handle response to Ebola outbreak
A former adviser to President Trump during the COVID-19 pandemic said Sunday that the U.S. is equipped to handle an Ebola outbreak. “The U.S. right now does not have a confirmed head of the [Centers f...
IBRX 2-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman
San Francisco, California--(Newsfile Corp. - May 24, 2026) - ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acqu...
Aurobindo Pharma's Eugia facility receives OAI classification from US FDA
Aurobindo Pharma has announced that its wholly owned subsidiary, Eugia Pharma Specialities Ltd., has received an 'official action indicated' (OAI) classification from the US Food and Drug Administrati...
Hims & Hers CEO is plotting new ways to upend traditional health care
Hims & Hers built massive weight-loss markets using telehealth. Peptides, if authorized by the FDA, stand to become a major part of the company’s shift to wellness and longevity.
FDA’s tobacco center just drafted new rules to let ecigs, pouches onto market, but staffers didn’t write them
Senior officials in the FDA's tobacco center were blindsided, the Associated Press has learned.
No child deaths definitively linked to Covid shots, FDA says
No child deaths have been definitively linked to Covid vaccines, according to a report from the Food and Drug Administration that was quietly made public last week.
GILD Receives FDA Approval for Hepcludex, First Treatment for Chronic HDV Infection
GILD Receives FDA Approval for Hepcludex, First Treatment for Chronic HDV Infection